… in the second treated eye in a Ph1b/2 extension trial in Leber Congenital Amaurosis type 10 (LCA10) Presenter: … Date: May 6, 2021 at 5:15pm EDT About Leber Congenital Amaurosis 10 (LCA10) Leber congenital …
Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan.
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;
Strategic convertible debt financing extends runway into 2023 if fully draw
… will be available for viewing until July 15, 2021. About Leber Congenital Amaurosis 10 (LCA10) Leber congenital amaurosis (LCA) is the most common cause of …
… include the following: Sepofarsen for CEP290 -mediated Leber congenital amaurosis 10 (LCA10): The Company expects to … disease target into preclinical development in 2022. About Leber Congenital Amaurosis 10 (LCA10) Leber congenital …